Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
about
Immunomodulation on the ocular surface: a reviewDevelopment of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye diseaseEnhanced Tearing by Electrical Stimulation of the Anterior Ethmoid NerveLifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled StudyLifitegrast: A novel drug for treatment of dry eye disease.Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.Lifitegrast for the treatment of dry eye disease in adults.LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye DiseaseLifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.Dry Eye Management: Targeting the Ocular Surface Microenvironment.Integrins as Therapeutic Targets: Successes and Cancers.Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.Dry eye syndrome: developments and lifitegrast in perspective.An efficient synthesis of 6-arylbenzo[4,5]imidazo[2,1-a]isoquinolines via sequential α-arylation of carbonyl and deacylation catalyzed by CuI.Current Anti-Integrin Therapy for Ocular Disease.Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.[Novel current and future therapy options for treatment of dry eye disease].Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products.Current and emerging therapy of dry eye disease. Part A: pharmacological modalities
P2860
Q26740643-68E172FB-F847-42EB-903B-62F67C966E8EQ26746232-B47BB824-40E8-4B9D-8115-7A0CFE213E53Q33585580-738689F8-7F54-4A4F-A381-90C7642D9ECAQ33739879-CCEC3AA8-BC28-4D90-9EFB-169F94F53A9FQ36252489-760372D1-3A36-4BF0-A84E-1A8D42B92C39Q36877000-B6AF265A-2912-430C-9FEE-E3CCF61A341EQ37591609-FD6C1833-307E-49C6-9833-7D74C2A9E01CQ37610134-E526492A-5943-4192-B164-94D358480DABQ38608475-C115DCB1-2319-4C85-849E-590D4ADFC1E9Q39025675-CBE2F592-7F78-48F9-8240-4895DD0AD479Q39069560-235E871F-065D-4CFC-A8C9-B2C5F05F248DQ39404635-4AF39DF6-AB54-47BB-ABED-435CE913FF27Q41670949-D64FAFE1-0867-4CB0-AD67-60CA6C489E54Q45037685-449EFDD0-91FF-45E1-A19F-0D09B4CF0678Q47268214-51B8124B-31F0-4FAF-ACF5-F5E0FFFD4B25Q47639135-FEB35FCE-292B-4B3A-B75B-7877D138A237Q48019769-EC6CCA7D-7CC4-4663-94FF-DD82798A9DDAQ48095233-6FCC798C-6233-4230-B0C2-649440909F61Q49261503-44E13746-BAA5-4675-BEA5-7397B7E94085Q50039889-DB8E1548-ED42-4870-9BB1-377A0D042434Q52661549-57715456-BF9B-4E4D-8166-A32E88DF6DBEQ57378488-0A804336-3597-43A4-8A0D-BBA759D17517
P2860
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@ast
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@en
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@nl
type
label
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@ast
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@en
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@nl
prefLabel
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@ast
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@en
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@nl
P2093
P1433
P1476
Lifitegrast Ophthalmic Solutio ...... omized Phase III OPUS-2 Study.
@en
P2093
Aparna Raychaudhuri
Charles P Semba
Jodi Luchs
Joseph Martel
Joseph Tauber
Kenneth Sall
OPUS-2 Investigators
Paul Karpecki
Robert Latkany
Valerie Smith
P304
P356
10.1016/J.OPHTHA.2015.08.001
P577
2015-09-10T00:00:00Z